Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2000-01-04
2001-04-10
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S229000
Reexamination Certificate
active
06214883
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to methods useful in combating
Pneumocystis carinii
pneumonia and prodrug compounds useful therefor.
BACKGROUND OF THE INVENTION
Pentamidine is used for the treatment of
Pneumocystis carinii
pneumonia, or “PCP”. The importance of pentamidine has dramatically escalated recently due to the marked increase of patients suffering from PCP. The increase in the afflicted patient population is an unfortunate consequence of the increasing presence of the Acquired Immunodeficiency Syndrome (“AIDS”). It is now estimated that approximately 70 percent of AIDS patients contract PCP. Because of the high incidence of PCP in AIDS patients, pentamidine has found utility not only in the treatment of PCP, but also as prophylaxis, in preventing or delaying the initial onset or recurrence of PCP, especially in AIDS patients. Currently, pentamidlne is most commonly administered as a therapeutic agent by intravenous infusion and as a prophylactic agent by aerosol dosage.
However, an unfortunate side effect of pentamidine is its toxicity. Some fatalities have been attributed to severe hypotension, dysglycemia, and cardiac arrhythmias in patients treated with pentamidine. Contrawise, insufficient dosage may result in dissemination of disease beyond the lung, an occurrence which is associated with a poor prognosis. Therapeutic drug monitoring is not used because of the cost and complexity of the currently available assay techniques which require the extraction of plasma and High Performance Liquid Chromatography (HPLC) analysis. As a result, the toxicity of pentamidine is a significant concern, which is driving the market toward the development of pentamidine substitutes capable of avoiding or minimizing the undesirable side effects associated with the use of pentamidine. See, e.g., J. Spychala et al.,
Eur. J. Med. Chem.
29, 363-367 (1994); I. O. Donkor et al.,
J. Med. Chem.
37, 4554-4557 (1994); R. R. Tidwell et al.,
J. Protozool.
6, 148S-150S (1991).
Accordingly, it is an object of the present invention to provide new compounds useful in the treatment of
P. carinii
pneumonia.
SUMMARY OF THE INVENTION
A method of treating
Pneumocystis carinii
pneumonia in a subject in need of such treatment is disclosed. The method comprises orally administering to the subject a bis-benzamidoxime, derivative thereof, or a pharmaceutically acceptable salt thereof (hereinafter referred to as the “active compound”), that is reduced in the subject to produce a benzamidine having anti-
P. carinii
activity. The method of the present invention may alternatively comprise intravenously administering to the subject an active compound as disclosed herein.
A second aspect of the present invention is a pharmaceutical formulation comprising, in combination with a pharmaceutically acceptable carrier, a bis-benzamidoxime, or a pharmaceutically acceptable salt thereof, that is reduced in a mammalian subject after administration thereto to produce a benzamidine having anti-
Pneumocystis carinii
activity, subject to the proviso that said bis-benzamidoxime is not 1,5-bis(4′-(N-hydroxyamidino)phenoxy)pentane.
A third aspect of the present invention are active compounds useful in carrying out a therapeutic method of the present invention.
A fourth aspect of the present invention is the use of an active compound as disclosed herein for the manufacture of a medicament useful in carrying out a therapeutic method of treatment as given above.
REFERENCES:
patent: 2425223 (1947-08-01), Barber
patent: 2449724 (1948-09-01), Short et al.
patent: 2851495 (1958-09-01), Jensch et al.
patent: 3767616 (1973-10-01), Zellner
patent: 4034010 (1977-07-01), Hamano et al.
patent: 4064169 (1977-12-01), Hamano et al.
patent: 4237168 (1980-12-01), Reifschneider
patent: 4546113 (1985-10-01), Glazer
patent: 4933347 (1990-06-01), Tidwell et al.
patent: 5262157 (1993-11-01), Bernard et al.
patent: 5364615 (1994-11-01), Debs et al.
patent: 5366726 (1994-11-01), Debs et al.
patent: 5786383 (1998-07-01), Clement
patent: 0 366 066 A1 (1989-10-01), None
patent: 2018401 (1971-12-01), None
patent: WO 94/08580 (1994-04-01), None
patent: WO 95/08540 (1995-03-01), None
patent: WO 95/01168 (1995-04-01), None
B. Clement et al.; Amidoximes of Pentamidine: Synthesis, Trypanocidal and Leishmanicidal Activity,Arzneim.-Forsch/Drug Res.35(II), No. 7: 1009-1014 (1985).
B. Clement et al.; Reduction of Amidoxime Derivatives to Pentamidine in vivo,Arch. Pharm.(Weinheim) 325: 62-62 (1992).
B. Clement et al.; N-Hydroxylation of the Antiprotozoal Drug Pentamidine Catalyzed by Rabbit Liver Cytochrome P-450 2C3 or Human Liver Microsomes, Microsomal Retroreduction, and Further Oxidative Transformation of the Formed Amidoximes,Drugs Metabolism and Diposition22:486-497 (1994).
A.T. Fuller et al.; Chemotherapeutic Agents if the Sulphone Type. Part II. Sulphones Related to Benzamidine and Benzylamine,J. Chem. Soc.633-640 (1945).
C.H. Andrewes et al.; Experimental chemotherapy of typhus. Anti-rickettsial action of p-sulphonamidobenzamidine and related compounds,Proc. Royal Soc.(London) 133B:20-62 (1946).
N.P. Buu-Hoi et al.; Une nouvelle famille de composes tuberculostatiques: les amidoximes,Experientia10:169 (1954).
P. Chabrier et al.; Nouvelles recherches sur les rapports entre structure chimique, activite'antibacterienne, antifungique et toxicite', dans la serie des esters de l'acide dithiocarbamique N-disubstitue',Ann. Pharm. Franc.14:720-728 (1956)..
I.D. Lamb et al.; Some Amidines and Amidoximes with Trypanocidal Activity ,J. Chem. Soc.1253-1257 (1939).
David W. Boykin et al.; Dicationic Dairylfurans as Anti-Pneumocycstis carinii Agents,J. Med. Chem., 38:912-916 (1995).
P M S Chauhan et al.; Synthesis of 2,8-Diamidinodibenz b,floxepin & Related Compounds as Potential Leishmanicides,Indian Journal of Chemistry, 22B:898-900 (Sep. 1983).
P M S Chauhan et al.; Antiparasitic Agents:Part VI.-Synthesis of 1,2-,1,3-& 1,4-Bis(4-substituted aryloxzy)benezenes & Their Biological Activities,Indian Journal of Chemistry, 27B:38-42 (Jan 1988).
Clement et al.; Metabolic N-Hydroxylation of Diminazene in vitro,Arzneim.-Forsch./Drug Res.,42(II),No. 12:1497-1504 (1992).
Boykin David W.
Hall James E.
Tidwell Richard R.
Myers Bigel & Sibley & Sajovec
Raymond Richard L.
The Georgia State University
LandOfFree
Benzamidoxime prodrugs as antipneumocystic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Benzamidoxime prodrugs as antipneumocystic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Benzamidoxime prodrugs as antipneumocystic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2440760